FDA — authorised 30 November 1984
- Application: NDA018883
- Marketing authorisation holder: FRESENIUS MEDCL
- Status: supplemented
FDA authorised Tesomet "Low dose" in fasted condition on 30 November 1984
Yes. FDA authorised it on 30 November 1984; FDA authorised it on 31 January 2011; FDA authorised it on 31 January 2017.
FRESENIUS MEDCL holds the US marketing authorisation.